Pablo Peñafiel-Verdú
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pablo Peñafiel-Verdú has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Mariano Valdés
8 shared publicationsArcadio García-Alberola
7 shared publications- Domingo Andrés Pascual Figal
Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
6 shared publications - Carmen Muñoz-Esparza
Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
5 shared publications Juan J. Sánchez-Muñoz
5 shared publicationsJuan Martínez-Sánchez
5 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 14 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Conduction system pacing, a European survey: insights from clinical practice
Aims: The field of conduction system pacing (CSP) is evolving, and our aim was to obtain a contemporary picture of European CSP practice. Methods and results: A survey was devised by a European CSP Expert Group and sent electronically to cardiologists utilizing CSP. A total of 284 physicians were invited to contribute of which 171 physicians (60.2%; 85% electrophysiologists) responded. Most (77%) had experience with both His-bundle pacing (HBP) and left bundle branch area pacing (LBBAP). Pacing indications ranked highest for CSP were atrioventricular block (irrespective of left ventricular ejection fraction) and when coronary sinus lead implantation failed. For patients with left bundle branch block (LBBB) and heart failure (HF), conventional biventricular pacing remained first-line treatment. For most indications, operators preferred LBBAP over HBP as a first-line approach. When HBP was attempted as an initial approach, reasons reported for transitioning to utilizing LBBAP were: (i) high threshold (reported as >2 V at 1 ms), (ii) failure to reverse bundle branch block, or (iii) > 30 min attempting to implant at His-bundle sites. Backup right ventricular lead use for HBP was low (median 20%) and predominated in pace-and-ablate scenarios. Twelve-lead electrocardiogram assessment was deemed highly important during follow-up. This, coupled with limitations from current capture management algorithms, limits remote monitoring for CSP patients. Conclusions: This survey provides a snapshot of CSP implementation in Europe. Currently, CSP is predominantly used for bradycardia indications. For HF patients with LBBB, most operators reserve CSP for biventricular implant failures. Left bundle branch area pacing ostensibly has practical advantages over HBP and is therefore preferred by many operators. Practical limitations remain, and large randomized clinical trial data are currently lacking.
- 14 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Top Cited PapersOpen AccessConduction system pacing, a European survey: insights from clinical practice
Aims: The field of conduction system pacing (CSP) is evolving, and our aim was to obtain a contemporary picture of European CSP practice. Methods and results: A survey was devised by a European CSP Expert Group and sent electronically to cardiologists utilizing CSP. A total of 284 physicians were invited to contribute of which 171 physicians (60.2%; 85% electrophysiologists) responded. Most (77%) had experience with both His-bundle pacing (HBP) and left bundle branch area pacing (LBBAP). Pacing indications ranked highest for CSP were atrioventricular block (irrespective of left ventricular ejection fraction) and when coronary sinus lead implantation failed. For patients with left bundle branch block (LBBB) and heart failure (HF), conventional biventricular pacing remained first-line treatment. For most indications, operators preferred LBBAP over HBP as a first-line approach. When HBP was attempted as an initial approach, reasons reported for transitioning to utilizing LBBAP were: (i) high threshold (reported as >2 V at 1 ms), (ii) failure to reverse bundle branch block, or (iii) > 30 min attempting to implant at His-bundle sites. Backup right ventricular lead use for HBP was low (median 20%) and predominated in pace-and-ablate scenarios. Twelve-lead electrocardiogram assessment was deemed highly important during follow-up. This, coupled with limitations from current capture management algorithms, limits remote monitoring for CSP patients. Conclusions: This survey provides a snapshot of CSP implementation in Europe. Currently, CSP is predominantly used for bradycardia indications. For HF patients with LBBB, most operators reserve CSP for biventricular implant failures. Left bundle branch area pacing ostensibly has practical advantages over HBP and is therefore preferred by many operators. Practical limitations remain, and large randomized clinical trial data are currently lacking.
- 1 December 2019
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 72 (12) , 1020-1030
Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)
- 1 December 2019
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 72 (12) , 1020-1030
Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)
- 1 December 2019
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 72 (12) , 1020-1030
Resultados en España de la encuesta de la Sociedad Europea de Cardiología sobre terapia de resincronización cardiaca (CRT-Survey II)
- 1 December 2019
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 72 (12) , 1020-1030
Resultados en España de la encuesta de la Sociedad Europea de Cardiología sobre terapia de resincronización cardiaca (CRT-Survey II)
- 19 March 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (6) , 625-633
A scoring algorithm for the accurate differential diagnosis of regular wide QRS complex tachycardia
Background: The differential diagnosis of regular wide QRS complex tachycardia (RWQRST) remains the subject of numerous publications, all of which aim at diagnosis during the acute phase. Although an accurate diagnosis is necessary to make long‐term decisions, it often leads to invasive testing.Methods: Criteria with high positive predictive values (PPVs) for diagnosis can be obtained by analyzing the electrocardiogram (ECG) data during RWQRST and comparing them with these data at baseline. By assigning points to these criteria, a scoring algorithm to accurately diagnose numerous patients can be obtained. A total of 352 consecutive patients with RWQRST were included. Two electrophysiologists blind to patient condition analyzed the 16 criteria considered as having high PPVs.Results: A total of 149 (42.3%) cases were supraventricular tachycardia (SVT), and 203 (57.7%) cases were ventricular tachycardia (VT). A higher percentage of patients with VT had structural heart disease (86.7% vs 16.1%). Seven of the 16 criteria analyzed had PPVs > 95%, and each criterion was assigned a score. A final score of –1 was indicative of SVT (PPV 98%); a score of 1 was indicative of VT (PPV 98%); and a score of ≥2 was indicative of VT (PPV 100%). A score of ≠0 was obtained for 51.7% of all cases of tachycardia, making it possible to reach a highly accurate diagnosis in approximately half of all cases. No cases of VT scored –1, and no cases of SVT scored ≥2.Conclusions: The current scoring system stands out for its high PPV (98%) and specificity (98%), enabling an accurate diagnosis for more than half of the patients.
- 19 March 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (6) , 625-633
A scoring algorithm for the accurate differential diagnosis of regular wide QRS complex tachycardia
Background: The differential diagnosis of regular wide QRS complex tachycardia (RWQRST) remains the subject of numerous publications, all of which aim at diagnosis during the acute phase. Although an accurate diagnosis is necessary to make long‐term decisions, it often leads to invasive testing.Methods: Criteria with high positive predictive values (PPVs) for diagnosis can be obtained by analyzing the electrocardiogram (ECG) data during RWQRST and comparing them with these data at baseline. By assigning points to these criteria, a scoring algorithm to accurately diagnose numerous patients can be obtained. A total of 352 consecutive patients with RWQRST were included. Two electrophysiologists blind to patient condition analyzed the 16 criteria considered as having high PPVs.Results: A total of 149 (42.3%) cases were supraventricular tachycardia (SVT), and 203 (57.7%) cases were ventricular tachycardia (VT). A higher percentage of patients with VT had structural heart disease (86.7% vs 16.1%). Seven of the 16 criteria analyzed had PPVs > 95%, and each criterion was assigned a score. A final score of –1 was indicative of SVT (PPV 98%); a score of 1 was indicative of VT (PPV 98%); and a score of ≥2 was indicative of VT (PPV 100%). A score of ≠0 was obtained for 51.7% of all cases of tachycardia, making it possible to reach a highly accurate diagnosis in approximately half of all cases. No cases of VT scored –1, and no cases of SVT scored ≥2.Conclusions: The current scoring system stands out for its high PPV (98%) and specificity (98%), enabling an accurate diagnosis for more than half of the patients.
- 1 November 2017
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 70 (11) , 907-914
Valor del «test de bipedestación» en el diagnóstico y la evaluación de la respuesta al tratamiento con bloqueadores beta en el síndrome de QT largo
- 1 November 2017
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 70 (11) , 907-914
Valor del «test de bipedestación» en el diagnóstico y la evaluación de la respuesta al tratamiento con bloqueadores beta en el síndrome de QT largo
- 1 November 2017
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 70 (11) , 907-914
Value of the “Standing Test” in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome
- 1 November 2017
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 70 (11) , 907-914
Value of the “Standing Test” in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome
- 1 October 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (10) , 861-868
Fenotipo heterogéneo del síndrome de QT largo causado por la mutación KCNH2-H562R: importancia del estudio genético familiar
- 1 October 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (10) , 861-868
Fenotipo heterogéneo del síndrome de QT largo causado por la mutación KCNH2-H562R: importancia del estudio genético familiar
- 1 October 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (10) , 861-868
Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing
- 1 October 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (10) , 861-868
Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing
- 1 April 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (4) , 346-349
Mutación p.Arg14del en fosfolambán en una familia española con miocardiopatía arritmogénica: evidencia de una mutación europea fundadora
- 1 April 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (4) , 346-349
Mutación p.Arg14del en fosfolambán en una familia española con miocardiopatía arritmogénica: evidencia de una mutación europea fundadora
- 1 April 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (4) , 346-349
Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation
- 1 April 2015
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (4) , 346-349
Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation